Last reviewed · How we verify

NCT06724315: SCOPe

Prospective and Multicentric Cohort Study of Severe and Very Severe Chronic Obstructive Pulmonary Disease (COPD) in Brazil (SCOPe).

Recruiting now Last updated 5 June 2025
What this trial tests

trial in COPD (Chronic Obstructive Pulmonary Disease) in 693 participants. Currently enrolling.

Timeline
31 January 2025
Primary endpoint
15 July 2026
15 December 2026

Quick facts

Lead sponsorHospital Israelita Albert Einstein
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment693
Start date31 January 2025
Primary completion15 July 2026
Estimated completion15 December 2026
Sites1 location across Brazil

Conditions studied

Sponsor

Hospital Israelita Albert Einstein

Who can join

18 and older, any sex, with COPD (Chronic Obstructive Pulmonary Disease). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chronic obstructive pulmonary disease (COPD) is prevalent (8-20%) and is one of the leading causes of mortality. In 2019 according to WHO it was the third highest cause of death worldwide. In 2019 in Brazil respiratory diseases (Chapter J in the ICD10) were the third cause of death (176.073) with COPD (J44) accounting for 45.163 deaths (25,6% of respiratory and 3% overall). There is an upward trend for COPD mortality worldwide. The disease also has a high morbidity leading to impairment in daily activity and quality of life. Patients with severe and very severe disease are at a higher risk for negative outcomes, including exacerbation (up to 2-3 per patient per year). This in turn increases the risk of future exacerbations and mortality, with heightened risk lasting up to two years after each event. It is impertive to evaluate which sub-groups are at an even higher risk and could be potential targets for intervention. "The PLATINO study" was conducted on 2004 and evaluated the prevalence of COPD in 5 cities, only one in Brazil - Sao Paulo. As the data is 20 years old it might not reflect the current epidemiological status and might not be representative of Brazil as a whole. Understanding this population, their clinical and laboratorial characteristics can help identify sub-groups with higher risk and potential for intervention. The current prevalence, causing agent and characteristics are not known in Brazil as well as detailed outcome data.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for COPD (Chronic Obstructive Pulmonary Disease)

Currently open trials in the same condition.

Other Hospital Israelita Albert Einstein trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06724315.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing